DESCRIPTION

Written by the winner of the 2008 Mike Price Fellowship

"This volume provides a comprehensive overview of the wealth of information now available in this important and fast-moving subject."  Anticancer Research, November - December 2008

This book provides a clear introduction to the area, with an overview of the various drug design and development approaches for cancer therapeutics and their progress in today’s multidisciplinary approach to cancer treatment.

Clearly structured throughout, the book not only provides information on currently used molecular treatment approaches, but also describes the various agents that are currently at various stages of development and clinical trials, thus making them the drugs of tomorrow.

The book goes on to present current therapeutic regimes including their indications and side effects, as well as their position in the international market in terms of sales and development costs. Furthermore, coverage of our advancement in the understanding of cancer biology and how this has driven the drug discovery process is clearly discussed. Modern drug discovery aspects, through genomic, proteomic and metabolomic approaches are referred to as well as combinatorial chemistry techniques and discovery of chemotherapeutic agents from plant extracts, re-use of old drugs and drugs from other indications, or de novo rational drug design.
Including contributions from leading experts in the field, this book provides the reader with a complete overview of the various types of therapeutic agents, current and emerging, as well as other aspects associated with anticancer therapy, drug design, resistance and clinical trials in oncology.

About the Author

Dr Sotiris Missailidis. Department of Chemistry and Analytical Sciences, The Open University, Milton Keynes, UK.

Features

- Includes information on the emerging therapeutics currently in various stages of clinical trials including chemical and crystal structures.

- Multidisciplinary approach to the subject with discussion of development of resistance, design of new drugs and overview of their pharmacological properties in conjunction with current and emerging therapeutics.

- Clear presentation of different groups of molecular cancer therapy in a single volume to enable comparison of the current with the developmental.

- Includes contributions from both academic and industrial researchers in the field to ensure a broad and balanced overview of the subject.

- Includes contributions from those currently working in drug development in association with the pharmaceutical industry and biotech spin-off companies.

- A unique approach to the subject- existing texts in the fields focus either on the anticancer drug development process or the pharmacology, pharmacokinetic and pharmacodynamic studies of anticancer drugs.

- Modern drug discovery aspects are discussed, through genomic, proteomic and metabolomic approaches.

- Examines both Chemical and Biological agents.

- Clearly structured throughout including coverage of different classes of anticancer therapeutics, a description of the target (or target class) and the characteristics that make such targets appropriate for the development of anticancer agents.

From AQ:
• The book provides a comprehensive list of anticancer therapeutic categories

• It includes both small molecule chemotherapy and biological therapies

• It provides structures of molecules included

• It gives information on uses, side effects, resistance etc. on drug categories included

• It includes both established molecules and molecules currently in clinical trials that would be the Anticancer Therapeutics in the years to come

• It is written by international authorities in their particular drug categories

• It provides information on drug design, clinical trials and pharmaceutical market

For additional product details, please visit https://www.wiley.com/en-us